Alternative to Rituximab Therapy for a Patient with Ankylosing Spondylitis Who Was Unable to Continue Anti-TNF Therapy by Katsuyama, Eri et al.
A nkylosing spondylitis (AS) is a chronic rheu-matic disease that mainly affects the sacroiliac 
joint and spine.  For axial manifestation of patients with 
AS,  there are no evidenced-disease-modifying 
anti-rheumatic drugs,  but the emergence of tumor 
necrosis factor alpha inhibitors (TNFi) has markedly 
improved the clinical symptoms of AS patients.  
Rituximab (RTX),  a monoclonal antibody for CD20 
that depletes B-cells,  is already known to be effective for 
various rheumatic diseases,  such as rheumatoid arthri-
tis and systemic vasculitis.
Recently,  RTX has been reported to show some 
response in TNFi-naive AS patients [1].  We herein 
report a case of AS in which the patient was unable to 
continue infliximab (IFX) due to adverse effects and was 
instead treated successfully with RTX.  This case report 
was approved by the ethics committee of Okayama 
University Graduate School of Medicine,  Dentistry and 
Pharmaceutical Sciences (#1703-025).
Case Report
A 38-year-old man visited our hospital complaining 
of severe back pain and difficulty in neck movement in 
February 2010.  He had been aware of lower back pain,  
which improved with exercise since 2002,  and had been 
suffering from repetitive uveitis since 2009.  On the first 
radiographic examination at our hospital in February 
2010,  he was already exhibiting a progressed “bamboo” 
spine (Fig. 1A , B) and disappearance of the sacroiliac 
joint space (Fig. 1C).  Therefore,  a diagnosis of AS was 
made promptly according to the modified New York 
criteria [2].
His symptoms were mainly axial involvements with-
out peripheral arthritis or other extra-articular lesions,  
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although he had a history of relapsing uveitis.  He had 
difficulties with neck and back flexion.  He did not have 
a history of psoriasis,  inflammatory bowel disease,  or 
relapsing aphtha.  He had never had urethritis.  His Bath 
Ankylosing Spondylitis Disease Activity Index 
(BASDAI) score was 6.06,  and his Bath Ankylosing 
Spondylitis Functional Index (BASFI) score was 5.14.  
HLA-A24,  HLA-B7,  and HLA-B51 were positive and 
HLA-B27 was negative.  Although NSAIDs,  8 mg of 
methotrexate (MTX) weekly,  5 mg of prednisolone 
(PSL) daily,  and 180 mg of loxoprofen daily were 
started in March 2010,  his axial symptoms did not 
improve.  Therefore,  in June 2010,  5 mg/kg of IFX,  a 
TNFi,  was added to his regimen.  The first administra-
tion of IFX led to rapid and significant improvement,  
and the patient’s BASDAI decreased from 7.74 to 5.10 
in 2 weeks.  However,  a few days after the first admin-
istration of IFX,  he felt numbness and pain in the upper 
and lower limbs with “glove and stocking” distribution.  
A neurological examination showed mild hypopalles-
thesia of the lower limbs and a decreased Achilles ten-
don reflex.  However,  nerve conduction studies and 
magnetic resonance imaging (MRI) of the spine showed 
no abnormalities.  Although the numbness and pain in 
his extremities gradually improved as the days passed 
after the first IFX administration,  his numbness became 
exacerbated after the second administration,  2 weeks 
after the first.  In June 2011,  even after IFX was replaced 
with 50 mg of etanercept (ETN),  another TNFi,  the 
numbness and pain in his extremities relapsed.  ETN 
was then discontinued,  and the numbness improved.  
Two months after ETN was discontinued,  the 
patient’s BASDAI score remained high (5.40) with active 
axial symptoms.  Therefore,  after informed consent was 
obtained,  375 mg/m2 of RTX was administered intra-
venously twice at biweekly intervals in October 2011.  
Two weeks after the first RTX administration,  the 
patient’s peripheral blood B-cells were completely 
depleted (from 323 to 0 cells/µl).  His BASDAI score 
decreased from 6.39 to 3.56,  and his serum C-reactive 
protein (CRP) levels also decreased,  from 2.2 to 0.49  
mg/dl.  His back pain had kept improved for 10 months 
since the first RTX administration,  even after the daily 
dosage of oral glucocorticoid was tapered from 4 to 
2 mg and methotrexate was discontinued.  In December 
2012,  the patient suffered from gradually exacerbating 
neck and back pain,  which was correlated with the 
recovery of B-cells in the peripheral blood.  His 
BASDAI and serum CRP levels were increased to 7.03 
and 1.72 mg/dl,  respectively.  He was administered a 
second course of RTX therapy,  after which his BASDAI 
decreased promptly to 2.56 (Fig. 2).  
Discussion
For predominant axial disease in patients with AS,  
NSAIDs and TNFi are recommended by ASAS/EULAR 
[3].  A previous meta-analysis indicated that a TNFi,  
such as adalimumab,  ETN,  or IFX,  exhibited similar 
efficacy [4 , 5].  However,  20-40% of all patients with AS 
treated with a TNFi changed their treatment due to 
inefficacy [6],  and some patients had difficulty continu-
ing with TNFi because of adverse effects.  The present 
patient complained of numbness in his hands and feet 
after TNFi therapy,  which was suspected to be TNF-
related demyelinating disease.  Our patient reported this 
numbness a few days after the initiation of TNFi ther-
apy,  so we surmised this symptom to indicate TNF-
related neuropathy,  though we found no abnormal 
findings with MRI and a nerve conduction study.  
Numerous case reports have reported demyelinating 
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Fig.  1　 A radiograph of the spine shows A) cervical synostosis 
and B) linearization of the lumbar spine.  Magnetic resonance imag-
ing shows C) inﬂammation and narrowing of the sacroiliac joint.
adverse effects in patients taking a TNFi,  and there is a 
report,  similar to our case,  in which a patient treated 
with IFX developed a small-fiber sensory symmetrical 
polyneuropathy with normal electrophysiological stud-
ies [7].  The timing of the onset of TNFi-related neu-
ropathy varied considerably,  and there is even a case of 
extremely early onset of neuropathy,  in which neurop-
athy started to worsen 8 h after the first infusion [8].  In 
our case,  neuropathy occurred relatively early as an 
adverse effect of IFX.
In addition to TNFi,  various biologic agents,  such as 
secukinumab,  ustekinumab,  anakinra,  sarilumab,  
tocilizumab,  and abatacept,  have been evaluated as 
alternative treatments for patients with AS [9-15].  
However,  they do not appear able to exceed the efficacy 
of TNFi at present.  
RTX elicited a good response in the present case,  
though complete remission was not achieved.  The effi-
cacy of RTX in AS patients was reported in several cases 
[16-18].  Radiographic improvement with RTX has been 
demonstrated,  resulting in a marked improvement of 
the high signal intensity on sacroiliac joint inflamma-
tion in clinical symptoms as well as MRI findings in 
active AS patients with axial disease and left knee 
arthritis without TNFi [19].  Although RTX did not 
show a therapeutic effect in any of the 10 patients with 
TNF failure studied,  some response was noted in 10 
TNF-naïve patients in an open study [1].  Another open 
study demonstrated that RTX had greater efficacy in 
TNF-naïve than TNF-failure patients [20].  Therefore,  
we considered that RTX is indicated in patients with AS 
who,  despite responding well to TNFi treatment,  had 
difficulty continuing TNFi due to adverse effects.
Pathologically,  several reports have demonstrated an 
association between B-cells and AS.  Some reports 
showed that T-cells and macrophages were histologi-
cally dominant in active sacroiliitis of AS and spondy-
loarthritis [21 , 22],  whereas CD20+B-cells were also 
detected immunohistochemically in the spine of AS 
patients.  Heiner A et al.  reported a significant difference 
in the number of CD20+B-cells between AS patients 
with persistently inflamed joints and AS patients with-
out active joint inflammation [23].  It has been reported 
that the percentage of CD19+B-cells in AS patients was 
positively correlated with BASDAI scores [24].  In addi-
tion to the presence of B-cells in inflammatory regions,  
it has been revealed that immunoglobulin variable 
heavy chain (IgVH) 2 was overexpressed in the periph-
eral blood of AS patients,  indicating that different rear-
rangements in IgVH genes might cause abnormal 
molecular events in B-cells [25].  In the present case,  
the axial symptom flared as the peripheral B-cell num-
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Fig. 2　 Clinical course.
ber increased.  These reports suggested that B-cell acti-
vation is partially related to the pathology of AS.  
Therefore,  B-cell depletion could be a potential targeted 
treatment for AS.  
In conclusion,  we experienced a patient with AS 
who was forced to discontinue TNFi treatment but ulti-
mately had an acceptable response to RTX.  Because 
B-cells may play an important role in the pathogenesis 
of AS,  RTX may be an alternative treatment option.   
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